Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas: Are valuations attractive? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 26, 2001

    Nicholas: Are valuations attractive?

    Nicholas strategy of growing through the inorganic route seems to be paying off well for the company. The recent Rs 2.4 bn acquisition of Rhone Poulenc is expected to catapult its turnover into top 5 pharma companies in India. Post merger with Rhone Poulenc, Nicholas growth numbers were quite stupendous.

    Exciting Numbers- The merger effect
    Rs. m % Growth
    Sales 74.9%
    Operating Profits 53.2%
    PBT (before extra-ordinary items 77.6%

    The acquisition cost of Rs 2.4 bn for Rhone Poulenc was funded through a mix of debt (around Rs 2 bn), internal accruals and cash balance in the books of Rhone Poulenc. The beauty of the deal is a shorter pay back period expected for Nicholas Piramal. The company is expected to receive a one-time cash flow of Rs 1.2 bn from reduction in working capital and sale of properties while annual benefits are expected to be in excess of Rs 0.3 bn annually.

    Rhone Poulenc Investment- A fast payback
    Particulars Rs m.
    Acquisition Cost plus VRS & restructuring cost 2,800
    One Time Cash inflow for Nicholas
    Sale of Property at Worli 850
    Reduction in Working Capital 300
    Initial Liquid Assets 400
    Property at Bhandup (value currently not ascertained) NA
    (Source: company)

    Immediate cash flows from sale of property and effective utilisation of internal accruals is expected to ensure considerable savings in interest costs for Nicholas Piramal in the next year. Apart from that annual cost savings due to synergies in operations are expected to be in the range of Rs 300-400 m. All the functions except sales and marketing operations of the company have been merged with Nicholas to derive cost benefits. Effectively, all this is expected to ensure robust one time growth in EPS for FY03.

    The merger of Rhone Poulenc made sense for Nicholas Piramal, which helped the company in creating a robust revenue base without putting a considerable strain on its financials. Apart from that it helped the company in gaining entry into some key therapeutic areas like anti-histamines, CNS, respiratory and Gastro Intestinal areas. Some of its key brands like Phensedyl, Gardenal, and Stemetil added to the strong brand portfolio list of Nicholas.

    Apart from this Nicholas also has investments in host of subsidiaries and other strategic investments, which have been a key strategy for growth over the years. Cumulatively, the returns from investments in its subsidiaries have been satisfactory. Some investments like Charak Piramal are at a nascent stage, which could generate good revenues for the company going forward.

    Nicholas Piramal- Hidden Assets
    Subsidiaries/ Strategic Investments Effective
    Holding (%)
    Sum Invested
    (Rs. m)
    NPIL Share of
    PAT (FY01)
    Gujarat Glass (incl. Ceylon Glass) 54 93 †82
    Dr. Trivedi (Pathology Labs) 90 23 †19
    Dr. Phadke 60 56 †3
    Reckitt Piramal 40 40 4
    Sarabhai Piramal 50 225 97
    Boots Piramal 40 17 17
    Allergan India 49 39 26
    Solumiks Piramal* 50 32 -1
    Charak Piramal 50 43 -5

    * - Nicholas has announced sell of its stake in Solumiks Piramal, a joint venture for ayurvedic products to its joint venture partner at a price exceeding Rs 30 m. Nicholas would concentrate on Charak Piramal venture for the ayurvedic segment.

    Going forward Nicholas intends to focus primarily only on the domestic market. The therapeutic areas, which Nicholas caters to, are well diversified. It has launched several new products in last six months in the cardiovascular, anti-diabetic, anti-arthritic and anti-infective segments. Two anti-infective brands launched by the company viz, Gatrim and Gres (both glatifloxacin) are expected to help the company clock sales in excess of Rs 50 m in the first year of its launch.

    Sustained new product introductions should ensure reasonable growth for the company. However, one thing is clear that the growth in the company would be more or less in line with domestic pharma market, which in itself is not exciting. Further, the companyís operating margins donít compare favourably with that of its peers mainly due to its non-presence in the export markets.

    (Based on latest available results)

    On the R&D front, Nicholas has received bit of initial disappointment with the withdrawal of its first NCE molecule (Ablaquin, anti-malarial) from the market. Nicholasí research pipeline currently has 5 molecules. The most promising amongst them is one anti-cancer molecule. All the molecules are in pre-clinical stages and it would take time before one can expect revenues, even from out licensing of the pipeline.

    Research Initiatives- Good start, but at a nascent stage
    Cancer 1 molecule in advanced stages of pre-clinical trials
    CVS 2 molecules in pre-clinical trials
    Diabetes 1 molecule each in pre-clinical trials

    To summarise, the companyís investments and acquisition synergies are expected to start percolating into the financial numbers from early next year. Robust growth numbers (on account of merger without a major strain on balance sheet), a faster payback period, absence of extra-ordinary expenses are expected to make FY03 numbers of the company attractive.

    Comparative Valuations
    Particulars Nicholas Piramal* Wockhardt Sun Pharma
    CMP (Rs.) 231 405 571
    P/e (FY 02E) 11 16 14
    P/e (FY 03E) 8 14 NA
    Market Capitalisation (Rs. m) 8,778 14,702 26,722
    Mkt Cap/Sales (x) 1.0 2.4 3.5
    (*- Excl. extraordinary and one time items)



    Equitymaster requests your view! Post a comment on "Nicholas: Are valuations attractive?". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Compare Company With Charts